Hırvatistan - Hırvatça - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - tekući ekstrakt lista trputca i cvijeta crnog sljeza natrijev askorbat - sirup - 2,5 g + 65 mg/5 ml - urbroj: 5 ml sirupa (1 odmjerna žličica) sadrži: - 2,5 g tekućeg ekstrakta iz plantago lanceolata l. s.l., folium (list trpuca) i malva sylvestris l., flos (cvijet crnog sljeza) što odgovara 0,25 g lista trpuca i 0,25 g cvijeta crnog sljeza; ekstrakcijsko otapalo: voda - 65 mg askorbatne kiseline u obliku natrijevog askorbata

Hırvatistan - Hırvatça - HALMED (Agencija za lijekove i medicinske proizvode)

imunološki zavod d.d., rockefellerova 2, zagreb - cjepivo protiv tuberkuloze (bcg) cryodesiccatum - prašak i otapalo za suspenziju za injekciju - 0,75 mg (2-8 x 106 cfu) - urbroj: 1 ml rekonstituiranog cjepiva sadržava: 0,75 mg (2-8 x 106 cfu) živih, atenuiranih bakterija mycobacterium bovis (bcg), danski soj 1331

Hırvatistan - Hırvatça - HALMED (Agencija za lijekove i medicinske proizvode)

kedrion s.p.a., ai conti, castelvecchio pascoli, barga (lucca), italija - albumin, ljudski - otopina za infuziju - 200 g/l - urbroj: 1 l otopine za infuziju sadrži ukupno 200 g proteina plazme od kojih je najmanje 95% albumina, ljudskog

Hırvatistan - Hırvatça - HALMED (Agencija za lijekove i medicinske proizvode)

medika d.d. capraška 1 10000 zagreb -

Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

mylan ireland limited - финголимод hidroklorid - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 i 5. 1)orpatients s brzo razvija težak relapsing ublažavanje multiplom sklerozom određuje se 2 ili više teških recidiva u roku od jedne godine, s 1 ili više gadolinij revitalizacije lezija na mr mozga ili značajno povećanje opterećenja t2 lezija u odnosu na najnoviji mri.

Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

mylan ireland limited - финголимод hidroklorid - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 i 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

correvio - vernakalant hidroklorid - fibrilacija atrija - srčana terapija - brza transformacija nedavnog početka фибрилляции vrlo značajan u синусовый ritam i za odrasle:za non-kirurških bolesnika: fibrilacija atrija .

Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - cjepiva - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 i 5. 1 in product information document). korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.